Pulmonary interstitial glycogenosis

Summary

Pulmonary interstitial glycogenosis (MONDO:0016321) is a disease. A subtype of interstitial lung disease specific to infancy — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pulmonary interstitial glycogenosis
Mondo ID	MONDO:0016321
Orphanet	217557
ICD-10-CM	J84.842
ICD-11	1386580655
SNOMED CT	707551007
UMLS	C3161106
MedGen	838075
GARD	0020516
Is cancer (heuristic)	no

Also known as: infantile cellular interstitial pneumonitis · PIG · pig

Disease family

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › interstitial lung disease › interstitial lung disease specific to childhood › primary interstitial lung disease specific to childhood › interstitial lung disease specific to infancy › pulmonary interstitial glycogenosis

Related subtypes (4): neuroendocrine cell hyperplasia of infancy, chronic pneumonitis of infancy, persistent tachypnoe of infancy, cellular interstitial pneumonitis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.